616 related articles for article (PubMed ID: 27683798)
1. Long-term Efficacy of Vedolizumab for Crohn's Disease.
Vermeire S; Loftus EV; Colombel JF; Feagan BG; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):412-424. PubMed ID: 27683798
[TBL] [Abstract][Full Text] [Related]
2. Long-term Efficacy of Vedolizumab for Ulcerative Colitis.
Loftus EV; Colombel JF; Feagan BG; Vermeire S; Sandborn WJ; Sands BE; Danese S; D'Haens GR; Kaser A; Panaccione R; Rubin DT; Shafran I; McAuliffe M; Kaviya A; Sankoh S; Mody R; Abhyankar B; Smyth M
J Crohns Colitis; 2017 Apr; 11(4):400-411. PubMed ID: 27683800
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
4. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.
Wyant T; Yang L; Lirio RA; Rosario M
J Clin Pharmacol; 2021 Sep; 61(9):1174-1181. PubMed ID: 33908636
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3.
Sands BE; Van Assche G; Tudor D; Akhundova-Unadkat G; Curtis RI; Tan T
Inflamm Bowel Dis; 2019 Jul; 25(8):1375-1382. PubMed ID: 30615117
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of vedolizumab for inflammatory bowel disease.
Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
[TBL] [Abstract][Full Text] [Related]
10. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
13. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Watanabe K; Motoya S; Ogata H; Kanai T; Matsui T; Suzuki Y; Shikamura M; Sugiura K; Oda K; Hori T; Araki T; Watanabe M; Hibi T
J Gastroenterol; 2020 Mar; 55(3):291-306. PubMed ID: 31836930
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Rafia R; Scope A; Harnan S; Stevens JW; Stevenson M; Lobo A
Pharmacoeconomics; 2016 Dec; 34(12):1241-1253. PubMed ID: 27480631
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab in the treatment of Crohn's disease.
Tarabar D; Hirsch A; Rubin DT
Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
[TBL] [Abstract][Full Text] [Related]
19. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
